Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  CVS Health Corporation    CVS

CVS HEALTH CORPORATION

(CVS)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

CVS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against CVS Health Corporation - CVS

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/16/2019 | 10:51pm EDT

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 14, 2019 to file lead plaintiff applications in a securities class action lawsuit against CVS Health Corporation (NYSE: CVS), if they formerly held shares of Aetna Inc. that were exchanged for shares of CVS in connection with the November 2018 acquisition of Aetna by CVS. This action is pending in the United States District Court for the District of Rhode Island.

What You May Do

If you exchanged shares of Aetna for CVS shares as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nyse-cvs/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by October 14, 2019.

About the Lawsuit

CVS and certain of its executives are charged with failing to disclose material information, violating federal securities laws.

On March 13, 2018, shareholders of Aetna, Inc. approved its acquisition by CVS, receiving CVS stock valued at $80/share as part consideration. Subsequently, in August 2018 and again in February 2019, CVS disclosed the recording of impairment charges of $3.9B and $2.2B, respectively, related to its 2015 acquisition of Omnicare, Inc., sending shares of CVS plummeting.

The case is Waterford Township Police & Fire Ret. Sys. v. CVS Health Corp., et al., 19-cv-00434.

About Kahn Swick & Foti, LLC

KSF, whose partners include the former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORPORATION
09/16Opioid plaintiffs fight bid to disqualify U.S. judge before trial
RE
09/16IMPORTANT INVESTOR REMINDER : The Schall Law Firm Announces the Filing of a Clas..
BU
09/13The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CV..
BU
09/13Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against CV..
BU
09/12CVS HEALTH : Google Photos and CVS Pharmacy Team Up to Offer Same-Day Printing a..
PR
09/11Surescripts in Dispute With ReMy Health -CNBC
DJ
09/09Walgreens Boots Alliance on Pace for Largest Percent Increase in Over a Year ..
DJ
09/09CVS HEALTH : American College of Rheumatology - Rheumatology Leaders Concerned C..
AQ
09/09AETNA : Voices of Health Competition Kicks Off Today
PR
09/06ALPHABET, MATCH GROUP, CVS : Stocks That Defined The Week
DJ
More news
Financials (USD)
Sales 2019 253 B
EBIT 2019 15 012 M
Net income 2019 6 583 M
Debt 2019 63 327 M
Yield 2019 3,14%
P/E ratio 2019 12,5x
P/E ratio 2020 11,3x
EV / Sales2019 0,58x
EV / Sales2020 0,54x
Capitalization 82 556 M
Chart CVS HEALTH CORPORATION
Duration : Period :
CVS Health Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CVS HEALTH CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 71,69  $
Last Close Price 63,48  $
Spread / Highest target 44,9%
Spread / Average Target 12,9%
Spread / Lowest Target -8,63%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
Eva C. Boratto Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President